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Summary: We describe a simple iminunoturbidimetric method
for quantifying lipoprotein(a) in serum based on latex-enhanced
particle agglutination technology. Carboxylated latex particles
(diameter 240 nm) covalently coated with F(ab')2 fragments of
anti-lipoprotein(a) antibodies are incubated with the sample for
5 min at 37 °C, and the resulting agglutination is quantified by
measuring the change of turbidity produced at 700 nm. The
assay is rapid, precise and fully automated on the Hitachi 911
analyser. The assay range is about 0.03—0.9 g/1. Average ana-
lytical recovery was 97-8%. Precision (CV) ranged from 1.9 to
3.1% at different lipoprotein(a) values. There was no interfer-
ence from bilirubin, Intfalipid®, haemoglobin, plasminogen or
apolipoprotein B. Comparisons with a latex nephelometric as-
say carried out on the Behring nephelometer analyser, and with
three commercially available methods, a radioimmunoassay
and two ELISA assays, gave good correlations (r > 0.95), al-
though a large among-method variation in lipoprotein(a) values
was found. We conclude that the proposed latex turbidimetric
immunoassay method is suitable for routine use in clinical
laboratories.
These findings generated the need for a serum lipoprotein(a)
assay in the clinical chemistry laboratory. Various quantitative
immunological assays for lipoprotein(a) determination, includ-
ing electrophoretic techniques (10), radial immunodiffusion
(11), enzyme immunoassays (12), and radio immunoassays (13)
have been developed. However, these procedures generally re-
quire specialized reagents and equipment, long reaction times,
and multiple washing steps, and they are not easily automated.
Recently, in an effort to overcome these problems several au-
tomated fluid-phase immunoprecipitation procedures have been
described (14, 15).
In this study, we present a turbidimetric method which uses
particle-enhanced immunoassay technology and is carried out
on a last generation clinical chemistry analyser. This turbidi-
metric method has the advantage of being precise, rapid, easy
to perform, and suffers no interference from apolipoprotein B,
plasminogen, or from endogenous lipids, haemoglobin, or bil-
irubin. Here we describe the characteristics and performance
of the method.
Introduction
Lipoprotein(a) [Lp(a)] was initially though to be a genetic
variant of low density lipoprotein (LDL) (1). Lp(a) is a low
density lipoprotein-like particle containing apolipoprotein B-
100 disulphide-linked to one (or two) large glycoprotein called
apolipoprotein(a) (Mr 300000-700000) (2). Apolipoprotein(a)
has been shown to have a considerable degree of homology
with human plasminogen (3). The characteristic feature of lipo-
protein(a) is that it is distinct from all other serum proteins
and apolipoproteins. This protein is believed to be inherited as
an autosomal dominant trait and appears to be insensitive to
either diet, lifestyle or most hypolipidaemic drugs (4, 5).
Since its discovery by Berg in 1963 (1), there has been a
considerable rise in interest, not Only in specialized research
centres but also in clinical routine laboratories, in the accurate
measurement of lipoprotein(a) in blood. This interest was stim-
ulated by reports indicating that levels above 0.2—0.3 g/1,
present in approximately 25% of the population, are associated
with an increased risk of coronary heart disease (6, 7). Many
investigators have confirmed that a high lipoprotein(a) concen-
tration represents an indicator of risk for cardiovascular dis-
ease, especially when other serum lipidic quantities differ sig-
nificantly from the values for healthy subjects (8, 9).
Materials and Methods
Apparatus
We used an Hitachi 911 analysis system (Boehringer Mannheim,
D-68305 Mannheim, Germany) for all the determinations.
Samples
Blood was taken in red-top vacutainer tubes (Becton Dickinson,
Rutherford, NJ), allowed to clot, and the serum removed for
immediate assay or for storage at —30 °C if the analysis was
to be carried out later. Unselected serum specimens used for
comparative studies were obtained from the lipid laboratory of
our hospital.
Antibody
Rabbit polyclonal antiserum directed against human lipopro-
tein(a) was manufactured by Dakopatts A/S (Glostrup, Den-
mark). It showed no cross-reaction with apolipoprotein B or
plasminogen and was stored at 4°C. (Lot No. 012, 3.7 g/1 of
protein.)
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IgG was separated from this antiserum by precipitation with
half-saturated ammonium sulphate, followed by treatment with
Rivanol®. To obtain F(ab)'2 fragments, the purified IgG was
digested with twice-crystallized pepsin (EC 3.4.23.1) as de-
scribed previously (18). This preparation was tested, for purity
by immunoelectrophoresis against serum and plasma contain-
ing a high lipoprotein(a) concentration; only a single precipi-
tation line was formed.
Cal ibra tor
As calibrator we used N Lp(a) standard (Behringwerke AG,
Marburg, Germany) containing 0.827 g lipoprotein(a) per litre,
as determined by electroimmunodiffusion with reference to a
highly purified lipoprotein(a) preparation. In addition, a pool
of serum was used as a secondary standard. Its lipoprotein(a)
concentration (0.900 g/1) was determined by a nephelometric
method by repeated testing (five days, n = 10 each day) as
described elsewhere (16). This calibrator was aliquoted arid
stored in plastic vials at —30 °C or lyophilized in the presence
of 600 mmol/1 sucrose (17).
Latex reagent
Ten percent solid carboxylated polystyrene latex particles, 240
nm in diameter (CLM-006), were obtained from Polymer Lab-
oratories Ltd., Church Sireton, England. F(ab')2 fragments were
covalently coupled to latex particles as described previously
(18). The F(ab')2 fragments of the IgG fraction of the anti-
lipoprotein(a) antibodies were added in a protein/latex ratio of
1/10. The resulting 0.5% solid coated particle solution was
stored at 4 °C. This stock solution can be frozen or freeze-dried
for long term conservation.
Assay procedure
Sample processing, dilution, pipetting steps, and quantification
were performed automatically on the Hitachi 911 analyser. A
six point calibration curve was obtained by automatic dilution
of the calibrator (from 0 to 0.900 g/1; saline solution was used
for the zero). The assay procedure was as follows: after incu-
bation of 3 μΐ of the sample with 300 μΐ of the glycine buffer
(0.1 mol/1 glycine, 0.15 mol/1 NaCl, 10 g/1 bovine serum albumin
(Cohn Fraction V, Sigma Chemical Co., St. Louis, MO), 30 g/1
polyethylene glycol, 0.6 mmol/1 sodium azide, adjusted to pH
8.2) for 3 min, the reaction was started by the addition of 30 μΐ
of latex reagent and monitored at 700 nm for a further 5 min.
The test was run as a two point assay method with sample
blank correction.
Comparison methods
Correlation studies were carried out on two different groups of
52 and 80 patient serum samples, which had been stored at
—30 °C for up to 3 months. We compared the results obtained
by the present method with those of a latex nephelometric test
carried out on the Behring nephelometer analyser, and with
three different commercial assays performed according to the
manufacturers' instructions.
Latex nephelomelric assay
We measured lipoprotein(a) in serum samples by a latex-en-
hanced nephelometric immunoassay as previously described
(16). This method uses carboxylated latex particles covalently
coated with purified F(ab')2 fragments, the latter being derived
from a rabbit IgG antibody against lipoprotein(a) obtained
from Behring (Behringwerke AG, Marburg, Germany). This
assay is rapid (12 min), precise (CVs < 8%), uses a high sample
dilution (1/400) and is fully-automated on the Behring nephe-
lometer analyser. In addition, the method was free of turbid or
lipaemic interferences, and no significant differences were ob-
served when fresh and frozen samples were compared.
RIA test ' f
We used the Pharmacia apo (a) RIA 100 (Pharmacia Diagnos-
tics AB, Uppsala, Sweden) for the quantitative determination
of human apolipoprotein(a) in serum. This method is a two-
site immunoradiometric assay using two different monoclonal
antibodies directed against the apolipoprotein(a) part of the
lipoprotein(a) molecule. Values of apolipoprotein(a) protein are
expressed as U/l.
ELISA assays
We used the Macra™ Lp(a) assay (Terurno Medical Corp.,
Elkton, MD., USA), and the Biopool TintElize Lp(a) kit (Bio-
pool AB Umea, Sweden) according to the manufacturers' in-
structions. The MACRA Lp(a) kit is a sandwich ELISA that
utilizes a monoclonal antibody for capture and a polyclonal
antibody for detection (both directed against lipoprotein(a)).
The Biopool TintElize Lp(a) kit is a sandwich ELISA that
utilizes affinity purified polyclonal antibodies raised against
lipoprotein(a).
Furthermore, 20 hypertriacylglycerol samples, with triacyjgly-
cerol concentrations between 2.26 and 16.98 mmol/1, were as-
sayed with the turbidimetric test and results were compared
with those by the Macra™ Lp(a) assay.
Interfering substances
For interference studies we followed the procedure of Click
(19). We assessed the effect of bilirubin, Intralipid* (Kabi Phar-
macia, Stockholm, Sweden) and haemoglobin by adding known
amounts of these substances to a baseline serum pool containing
0.40 g/1 of lipoprotein(a). interference from plasminogen was
assessed by adding to the same pool various amounts of a
purified human plasminogen (Lys) preparation (Sigma Chem-
ical Co., St. Louis, USA). To assess the effect of apolipoprotein
B, we added increased amounts of a purified human apolipo-
protein B solution (International Enzymes Inc., Fallbrook,
USA) to a normolipaemic serum containing 0.09 g/l of lipo-
protein(a).
Statistics
The relationships between the turbidimetric method and the
four others assays were demonstrated by applying the non-
parametric method of Passing & Bablok (20). The correlation
coefficients of lipoprotein(a) values between methods were de-
termined by means of linear regression analysis. .
Results
Calibration curve
Using a six-point calibration procedure, the turbidimetric lip-
oprotein(a) assay has an analytical range of 0 to 0.900 g/1 (fig.
1). This covers the majority of normal and pathological serum
values. If the concentration exceeds 0.900 g/1, g. 5-fold dilution
a of the sample with saline is prepared and reanalysed automat-
ically by the instrument. The calibration curve is stable for up
to two weeks (reagents stored at + -2 to + 8 °C). In addition,
the system did not show the proz he phenomenon with lipo-
protein(a) concentrations of up to 3.500 g/1.
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Imprecision
The imprecision of the assay was examined with three serum
pool samples with different lipoprotein(a) values (tab. 1). For
within-run imprecision, which was determined by assaying 20
replicate samples, coefficients of variation ranged from 1.9 to
2.4%. Between-run imprecision was determined by assaying the
same samples on 20 consecutive days, and the coefficients of
variation were all < 4%. These data indicate that the precision
of the turbidimetric method is good and comparable with or
better than those obtained by other lipoprotein(a) methods
(10-13, 16).
In te r fe r ing substances
Due to the assay measuring principle (wavelength 700 nm),
there was no endogenous interference by bilirubin (up to 340
μπιοΐ/ΐ), haemoglobin (up to 9 g/1) or Intralipid® (up to 2% or
19.47 mmol/1 triacylglycerol equivalent) (fig. 2). In addition, no
effects were observed in any sample with spiked levels of up to
1.5 g/1 of apolipoprotein B, and 2.0 g/1 for plasminogen.
There was good agreement between the results obtained for 20
hypertriacylglycerol samples by the proposed method (y) and
those obtained by the Macra™ Lp(a) assay (x); (y = 1.386x
+ 0.04; r = 0.990; η = 20).
Lineari ty and sensi t ivi ty
Linearity was evaluated by serial dilutions (with saline solution)
of four different samples, which contained values of lipopro-
tein(a) in the range of analysis. Linear regression values of
lipoprotein(a) g/1 vs. dilution yielded correlation coefficients,
r > 0.995, for all samples. Within the assay's measuring range,
the deviations of measurement from theoretical values did not
exceed the 5% level. Calculation of the mean plus 3 SD of
twenty replicates of saline solution (zero signal) resulted in a
lower limit of detection of 0.03 g/1.
Recovery
The recovery of known concentrations of human serum stan-
dard added to aliquots of five pooled serum samples ranged
from 95.6 to 102.9% (mean = 97.8%).
Correlation
We assayed 52 and 80 sera with the turbidimetric latex immu-
no ssay on the Hitachi 911 (y) and with a latex nephelometric
test (x), an RIA test (x) and two ELISA methods (x). The
results of the method comparison studies are represented in
figure 3. Serum lipoprotejn(a) values ranged from 0.03 to 1.5
Tab. 1. Precision of the turbidimetric lipoprotein(a) assay
Lipoprotein(a) (g/1)
Mean SD CV (%)
Intra-assay
(n = 20)
Inter-assay
(n = 20)
0.158
0.403
0.692
0.160
0.413
0.698
0.0040
0.0075
0.0140
0.0050
0.0100
0.0160
2.4
1.9
2.0
3.1
2.4
2.3
1.0
0.8
| 0.6
< 0.4
0.2
0
0.2 0.4 0.6 0.8
Lipoprotein(a) lg/l]
1.0
Fig. 1. Lipoprotein(a) calibration curve for the latex turbidi-
metric method. Absorbance (mean ± 2 SD of 10 cali-
brations) versus calibrator concentrations.
120
Interfering substance, fraction of
highest concentration
Fig. 2. interference studies in the latex turbidimetric test for
lipoprotein(a). On the abscissa are represented the con-
centration of interfering substances, expressed as frac-
tion of highest concentration:
O —O Intralipid 2%;
D — D bilirubin, 340 μηιοΐ/ΐ;
e — o haemoglobin, 9 g/l;
Δ — Δ plasminogen, 2 g/l;
α —π Apolipoprotein B, 1.5 g/l.
g/l. Correlation coefficients (r) ranged from 0.95 (p < 0.001)
to 0.98 (p < 0.001), indicating a close correlation between all
the assays. However, we found slopes significantly different
(p > 0.05) from 1.0, indicating that there was no transferability
among the different methods. The apparent discrepancy in the
accuracy of the present method is symptomatic of the current
absence of a international standardization of lipoprotein(a)
assays.
Non-specific precipitations
We assayed different turbid specimens, 46 fresh and 79 frozen
sera, selected by visual inspection. The lipoprotein(a) values
obtained using the original turbidimetric method but replacing
the latex reagent by glycine buffer solution, were always less
than 0.03 g/1, indicating that the polyethyleneglycol solution
does not produce non-specific precipitation in the present tur-
bidimetric test.
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Fig. 3. Comparison of results according to a non-parametric regression analysis (19) for lipoprotein(a) assayed by the turbidimetric
method versus:
a) latex nephelometric immunoassay (y = 1.052 χ — 0.012; r = 0.975; n
b) RIA test (y = 0.495 χ + 0.011; r = 0.951; n = 52)
c) ELISA TintElize method (y = 1.380 χ - 0.012; r = 0.978; n = 80)
d) ELISA, Macra method (y = 1.483 χ - 0.025; r = 0.978; n = 80)
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Discussion
Lipoprotein(a) is a quantity of recent interest in atherosclerosis
and thrombosis, since it has been demonstrated to be an in-
dependent risk factor in both of these afflications (21). At
present, however, because of methodology and standardization
problems, the clinical application and role of lipoprotein(a)
measurements have not been as fully determination as those of
lipid and lipoprotein measurements. Conventional methods for
lipoprotein(a) measurement generally include tedious manual
enzyme or radioimmunoassay techniques. These procedures
require laboratory training for the production of reliable results.
To overcome this problem, several automated turbidimetric or
nephelometric immunoprecipitation assays have been devel-
oped recently (14, 15, 22).
A major problem of these assays for serum lipoprotein(a) is the
weak signal generated by the presently available commercial
antibodies. This leads to misinterpretation of results due to
ground noise signal, and/or non-specific precipitation due to
the need to use a high concentration of polyethylene glycol in
the reaction medium (22, 23).
The latex turbidimetric test presented here allows a fast and
convenient lipoprotein(a) determinations of high analytical
quality in small amounts of serum. The assay is fully automated
on the Hitachi 911 analysis system. The proposed method offers
advantages over non-enhanced turbidirnetric assays, since a
larger signal is produced with a smaller sample volume. Com-
parison of the performance of the latex turbidimetric test with
those of heterogeneous immunoassays for lipoprotein(a), such
as radio- or enzyme-immunoassays, shows that the new method
provides a considerable saving in time and labour without
sacrificing reliability. In addition, latex reagents have a long
shelf life, are easy to prepare, and as many as 300 tests can be
performed with 1 ml of antibody.
This simple and rapid method for quantifying lipoprotein(a) in
serum involves the use of F(ab')2 fragments of antibody cova-
lently coupled to latex particles of 240 nm diameter. Therefore,
this assay measure whole lipoprotein(a) molecules by the signal
generated from the immunoaggiutination of large latex parti-
cles. The heterogeneity caused by genetic isoforms of apoiipo-
protein(a) contributes only slightly to the overall size hetero-
geneity.
It is essential to maintain a stable suspension of the reactant
particles before use in the assay and to prevent non-specific
aggregation caused by other components in the sample during
the analysis. It has been recently reported that the use of F(ab')2
fragments of the antibody covalently coated onto latex particles
improves reagent stability (24). In our case, the stability of
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 12
Technical note 873
calibration curve is maintained for at least two months, when
the latex reagent is stored appropriately.
Neither haemoglobin, bilirubin nor Intralipid<8> interfered with
the assay. Also, the anti-lipoprotein(a) antiserum used in the
assay did not show cross-reactivity with, or interference from,
plasminogen or apolipoprotein B. On the other hand, the cor-
relation between the present method and the Macra™ Lp(a)
assay was not affected in 20 hypertriacylglycerolaemic samples
assayed.
We stored samples at —30 °C because we have previously found
no significant differences in the lipoprotein(a) concentratrions
of fresh and frozen samples (16).
The sensitivity limit, linearity, and precision of the test are good
and comparable to those of other homogeneous and hetero-
geneous immunoassays for lipoprotein(a) (10—13, 16).
Comparison of the turbidimetric method with a latex nephe-
lometric test and three existing commercial immunoassays for
lipoprotein(a) showed good correlations (r > 0.95), although a
large among-method variation in lipoprotein(a) values was ob-
tained. In order to reconcile the data obtained by the different
methods, the use of suitable reference materials with properly
assigned target values is necessary. Such material is not yet
available and our efforts must be directed towards the inter-
national standardization of lipoprotein(a) assays similar to that
recently performed for apolipoprotein A-I and B (25). It is,
however, clear that much more work is needed to achieve an
adequate standardization of lipoprotein(a) (26).
In conclusion, we have shown the feasibility of performing a
turbidimetric latex immunoassay for quantifying lipoprotein(a)
in serum on the Hitachi 911 analyser. The method is rapid, it
has a wide measuring range, good linearity and precision and
is fully automated. This particle-enhanced method not only
represents an interesting alternative to the widely used hetero-
geneous immunoassays for lipoprotein(a) quantitation, but is
also a practical method for routine application.
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